Table 6.
Sensitivity analysis
| Model parameters | Range of values | ICER (RM) |
|---|---|---|
| Dose regimen | 3-4 doses | 25,576 - 35,196 |
| Herd effects | ||
| Lower 95% bound on herd effects | ||
| Age 20-30 | 23% | 37,648 |
| Age 40-64 | 1% | |
| Age ≥ 65 | 11% | |
| Higher herd effects | ||
| Age 20-30 | 41% | 31,886 |
| Age 40-64 | 20% | |
| Age ≥ 65 | 31% | |
| Discounting of costs (benefits not discounted) | 3% | 33,140 |
| Vaccine serotype coverage | 61.7-71.7% | 34,208 - 36,242 |
| % cohort vaccinated | 80-100% | 31,711 - 32,751 |
| Vaccine efficacy | ||
| IPD | 82.7% to 99.9% | 34,377 - 40,896 |
| Pneumonia | -1.5% to 11% | 34,802 - 35,788 |
| Otitis Media | 4.1% to 9.7% | 35,184 - 35,209 |
| Disease incidence | ||
| Meningitis | 26,703 - 41.777 | |
| Bacteraemia | 50% to 200% of base case |
21,629 - 50,437 |
| Pneumonia | 34,723 - 35,433 | |
| Otitis Media | 35,166 - 35,212 |